+1 Recommend
1 collections

      Drug Design, Development and Therapy (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on the design and development of drugs, as well as the clinical outcomes, patient safety, and programs targeted at the effective and safe use of medicines. Sign up for email alerts here.

      88,007 Monthly downloads/views I 4.319 Impact Factor I 6.6 CiteScore I 1.12 Source Normalized Impact per Paper (SNIP) I 0.784 Scimago Journal & Country Rank (SJR)


      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Remimazolam Tosylate Combined with Low-Dose Propofol Improves Sedation and Safety in Hysteroscopy


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.



          Propofol is widely used for sedation of hysteroscopy. It can cause injection pain, respiratory depression, and hypotension. Remimazolam is a novel ultra-short-acting benzodiazepine. Clinical practice has found that the use of remimazolam alone often leads to body movement during hysteroscopy, which decreases the safety and comfort. Here this study is to investigate whether remimazolam combined with low-dose propofol can improve the sedation effect and safety of hysteroscopy.

          Patients and Methods

          In this prospective, randomized, parallel-controlled trial, women (18 to 60 years) undergoing hysteroscopy were randomly assigned to receive propofol (Group P), remimazolam tosylate (Group R), or remimazolam tosylate plus propofol (Group RP). Intraoperative sedation depth was kept at the bispectral index (BIS) value of 40–60. 6 μg/kg alfentanil was used for analgesic before sedation. Intraoperative low pulse oxygen saturation (SpO 2), body movement, injection pain, mean arterial pressure (MAP), heart rate (HR), and postoperative recovery time, dizziness, nausea and vomiting were recorded and compared.


          From February to July 2022, 193 patients were recruited and randomly assigned to group P (n=64), group R (n=64), or group RP (n=65). There was no significant inter-group difference of the intraoperative BIS values. The incidence of low SpO 2, injection pain, hypotension, and postoperative dizziness in group RP were less than that in group P, and had no significant difference from group R. The incidence of body movement in group RP was less than that in group R, and had no significant difference from group P. Postoperative recovery time of group RP was shorter than that of the other two groups. No significant inter-group difference in bradycardia, nausea and vomiting was observed.


          Remimazolam tosylate combined with low dose of propofol improved sedation and safety in hysteroscopy, and may be a more ideal sedative method for hysteroscopy.

          Most cited references25

          • Record: found
          • Abstract: not found
          • Article: not found

          Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial

            • Record: found
            • Abstract: not found
            • Article: not found

            Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening

              • Record: found
              • Abstract: not found
              • Article: not found

              Remimazolam for anaesthesia or sedation


                Author and article information

                Drug Des Devel Ther
                Drug Des Devel Ther
                Drug Design, Development and Therapy
                29 November 2022
                : 16
                : 4101-4108
                [1 ]Department of Anesthesiology, The Third Xiangya Hospital, Central South University , Changsha, Hunan, 410013, People’s Republic of China
                Author notes
                Correspondence: Jianbin Tong; Qin Liao, Department of Anesthesiology, The Third Xiangya Hospital, Central South University , No. 138 Tongzipo Road, Changsha, Hunan, 410013, People’s Republic of China, Email jianbintong@csu.edu.cn; xy3yyliaoqin@sina.com
                Author information
                © 2022 Zhang et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                : 19 September 2022
                : 05 November 2022
                Page count
                Figures: 1, Tables: 2, References: 25, Pages: 8
                Funded by: New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University;
                Funded by: Medical Empowerment and Talent Training Program;
                This study was supported by the New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University (No. 20180303); the Scientific Research Project “Medical Empowerment and Talent Training Program” of the Chinese Red Cross Foundation Medical Empowerment Public Welfare Special Fund.
                Clinical Trial Report

                Pharmacology & Pharmaceutical medicine
                remimazolam tosylate,propofol,sedation,hysteroscopy
                Pharmacology & Pharmaceutical medicine
                remimazolam tosylate, propofol, sedation, hysteroscopy


                Comment on this article